Cambridge, Mass.-based startup Glympse Bio has raised more than $45 million for its nanoparticle-based biosensors, and it’s hoping the alternative to traditional biopsies can help drug developers test whether their own medicines are actually treating a patient’s condition.
The company’s first biosensors will be tested in some of Gilead’s clinical trials for people with non-alcoholic steatohepatitis, the fatty liver disease known as NASH that is the target of many new experimental treatments.
About the Author Reprints
